DAY 1: Sunday, February 12, 2012

4^th International Conference on

Drug Discovery & Therapy

February 12–15, 2012, Dubai Men’s College, Dubai, UAE

www.icddt.com

TIME

INAUGURAL PROGRAM

10:00 -10.15 a.m.

Welcome Reception

Arrival of Participants and Guests

10.30 a.m.

Opening Ceremony

National Anthem

Opening Address

His Excellency Sheikh Nahayan Mabarak Al Nahayan

Minister of Higher Education and Scientific Research

Chancellor, Higher Colleges of Technology

Patron of the 4^th ICDDT

Keynote Addresses

Prof. Dr. Ferid Murad (Nobel Laureate), Co-President, 4^th ICDDT

Prof. Dr. Atta-ur-Rahman, FRS, Co-President, 4^th ICDDT

COFFEE BREAK: 11:00 – 11:45 a.m.

PLENARY SESSION

Time

Chairman: F. Murad

Co-Chairman: R. Chaguturu

Speaker

Title

11:45

12:30 p.m.

Location: Auditorium

Hartmut Michel (Nobel Laureate)

PL-1

Membrane Proteins: Importance, Functions, Structures

12:30

1:15 p.m.

Location: Auditorium

Robert Huber (Nobel Laureate)

PL-2

Intracellular Proteolysis, Structures, Mechanisms, and Drug Design  

LUNCH BREAK: 1:15 – 2:15 p.m.

Lecture Hall  1

(B-104)

Lecture Hall 2

(B-121)

Lecture Hall 3

(B-217)

Lecture Hall 4

(C-106)

Lecture Hall 5

(B-116)

Lecture Hall 6

(B-215)

Regenerative Medicine

CNS Drug Discovery & Therapy

Hot Topics in Natural Products

Hot Topics in Drug Targets / Recent Advances in Spectroscopy

Anti-Cancer Drug Discovery & Therapy / Translational Medicine

Medical Imaging / Innovative Drug Discovery & Nanotechnology / Pharmaceutical Biotechnology

Chairman: C. Prakash

Co-Chairman: S. Balani

Chairman: H.C. Pant

Co-Chairman: V. Radojevic

Chairman: M.I. Choudhary

Co-Chairman: T. Al-Tel

Chairman: H.A. Rothan

Co-Chairman: L.X. Tiefenauer

Chairman: C. van Haaften

Co-Chairman: T. Thalhammer

Chairman: A. Schrott-Fischer

Co-Chairman: M.J. Korbling

2:15

2:45

p.m.

Antonio Claudio Tedesco

IL-3

Evaluation of Advanced Nanomaterial to Controlled Release of Photoactive Compounds under Skin Dermal Equivalent to Improve Wound Healing and Burning Treatment of Skin Disorder in Tissue Engineering

2:15

2:45

p.m.

Hideaki Itoh

IL-4

Cisplatin, A HSP90 Inhibitor

2:15

2:45

p.m.

Tushar Kanti Chakraborty

IL-5

Challenges in Drug Discovery – from Natural Products to Designer Molecules

2:15

2:45

p.m.

Wael M. ElShamy

IL-6

BRCA1-IRIS Overexpression Promotes Formation of TN/BL Aggressive Breast Cancers

2:15

2:45

p.m.

Ola Larsson

IL-7

Perturbation of the Translatome by the Anti-diabetic Drug Metformin

2:15

2:35

p.m.

Fadwa Joud El Merabi

SL-8

3D Imagery of Live Cells Labeled with Gold Nanoparticles using Digital Holographic Microscopy

2:45

3:15

p.m.

Marcelo Einicker Lamas

IL-9

Crosstalk Between Bone Marrow-derived Stem Cells and Renal Epithelial Cells: Effects on Cell Death and Proliferation as a Perspective for Cell-based Therapies for Nephropathies

2:45

3:15

p.m.

Yoshiyuki Suzuki

IL-10

Chemical Chaperone Therapy for Neuronopathic Lysosomal Diseases

2:45

3:15

p.m.

Srivari Chandrasekhar

IL-11

Approaches for the Total Synthesis of Marine Natural Products as Leads in Pharmaceuticals

2:45

3:15

p.m.

Ewa Skrzypczak-Jankun

IL-12

Human Lipoxygenase: Structure, Function, Relevance to Human Diseases and Challenges in Drug Development

2:45

3:05

p.m.

Elie Hadchity

SL-13

Peptide Aptamers, Inhibitors of Hsp27: New Therapeutic Agents

2:35

2:55

p.m.

Hasan Aydin

SL-14

Identification  of Brain Mass Lesions by High MR Imaging Techniques; MR-Spectroscopy, DWI and ADC Mapping, Brain Perfusion, Preliminary Results

3:15

3:45

p.m.

Aris Lacis

IL-15

Three Years Experience of Using Stem Cells Therapy for Heart Failure and Pulmonary Hypertension in Children

3:15

3:45

p.m.

Messoud Ashina

IL-16

The PACAP Receptor: A Novel Target for Migraine Treatment

3:15

3:35

p.m.

Mohammadmehdi Fani

SL-17

Inhibitory Activity of Cinnamon zeylanicum and Eucalyptus globulus Oils on Streptococcus mutans, Staphylococcus aureus, and Candida species Isolated from Patients with Oral Infections

3:15

3:45

p.m.

Debomoy K. Lahiri

IL-18

MicroRNA to Study Physiological Regulation of Gene Products Implicated in CNS Disorders: Discovery of Novel APP and BACE-specific MicroRNAs Important for Alzheimer’s Disease

3:05

3:25

p.m.

Dipak Panigrahy

SL-19

Epoxy-eicosanoids Stimulate Multi-organ Metastasis and Tumor Dormancy Escape

2:55

3:15

p.m.

Marilita M. Moschos

SL-20

Clinical Value of Multifocal-electroretinogram (mf-ERG) in Retinal Diseases

3:45

4:15

p.m.

Stephen J. Faulkner

IL-21

A Prospective Case Series of Patients Treated with Adult Autologous, Culture Expanded Mesenchymal Stem Cells for Symptomatic Osteoarthritic Hip and Knee Joints Compared to an Untreated Comparison Group

3:45

4:05

p.m.

Mehmet Ozbilen

SL-22

Systematic Overview of Cochrane Reviews for Anticholinergic Effects of Antipsychotic Drugs

3:35

3:55

p.m.

 Basiouny El-Gamal

SL-23

Beneficial Effects of Omega-3 Fatty Acid Dietary Supplementation in Patients with Systemic Lupus Erythematosus

3:45

4:05

p.m.

Nooshin Bagherani

SL-24

The Newest Hypothesis about Vitiligo Most of the Suggested Pathogeneses of Vitiligo can be Attributed to Lack of One Factor: Zinc-a2-glycoprotein

3:25

3:45

p.m.

Mu Wang

SL-25

Superoxide Dismutase 1 as a Target for Chemosensitization of Platinum Resistant Ovarian Cancer Cells

3:15

3:35

p.m.

Marek Chorazy

SL-26

Study of Lung Cancer Metastasis to Adrenal Glands and to the Spleen

4:15

4:35

p.m.

Gali Pavlova

SL-27

Induction of Neutral Differentiation of Mammalian Adipose Stem Cells (ACSCs), and the Cell Behavior after Transplantation into Mouse Brain

4:05

4:25

p.m.

Eckhard Thiel

SL-28

Combined Systemic and Intrathecal Chemotherapy Followed by High-dose Chemotherapy for CNS Relapse of Aggressive Lymphomas: A Curative Approach?

3:55

4:25

p.m.

Sarwat Sultana

IL-29

Chrysin Protects Against Cisplatin-induced Colon Toxicity via Amelioration of Oxidative Stress and Apoptosis: Probable Role of p38MAPK and p53

4:05

4:35

p.m.

Vladimir V. Tsukruk

IL-30

Label-free Raman Mapping of Surface Distribution of Protein A and lgG Biomolecules and Selected Biomarkers

3:45

4:05

p.m.

Yinhua Yu

SL-31

Corilagin is the Major Active Compound from Phyllanthus niruri L. Extracts with Antitumor Activities in Hepatocellular Carcinoma

3:35

3:55

p.m.

Radu Rogojanu

SL-32

Advanced Application of Slide-Based Cytometry in Pharmaceutical Research and Clinical Studies Using TissueFAXS

4:35

4:55

p.m.

Fayez F. Safadi

SL-33

Osteoactivin, A Novel Protein for Stem Cell Differentiation and Bone Regeneration

4:25

4:45

p.m.

Tayfun Uzbay

SL-34

A New Target for Diagnosis and Treatment of CNS Disorders: Agmatinergic System

4:25

4:45

p.m.

Jun Wu

SL-35

Limonoids from Mangrove Plants of the Xylocarpus Genus and their Bioactivities

4:35

4:55

p.m.

Helena Dodziuk

SL-36

Modeling of Molecular and Chiral Recognition by Cyclodextrins

4:05

4:35

p.m.

Medhat Shehata

IL-37

Targeting P13-K/Akt/CK2/ PTEN Cascade and Tumor Microenvironment as a Novel Approach for Cancer Therapy

3:55

4:15

p.m.

Sevda Senel

SL-38

Applications of Chitosan Particulate Systems in Vaccines Delivery

4:45

5:05

p.m

J.M. Nguta

SL-35(a)

Cytotoxicity of Antimalarial Plant Extracts from Kenyan Biodiversity to the Brine Shrimp, Artemia salina L. (Artemiidae)

4:35

5:05

p.m.

Claudia Gragnoli

IL-39

Proteasome Modulator 9 is Linked to Insomnia Pathology of T2D

4:15

4:35

p.m.

Tsung-Lin Li

SL-40

Biosynthesis and Diversification of Lipoglycopeptide Antibiotics

The buses will leave for city tour at 5:00 p.m.

DAY 2: Monday, February 13, 2012

PLENARY SESSION

Time

Chairman: H. Michel

Co-Chairman: A. Rahman

Speaker

Title

9:00

9:45

a.m.

Location: Auditorium

Mario Molina (Nobel Laureate)

PL-41

Climate Change: Science, Policy and Solutions

9:45

10:30

a.m.

Location: Auditorium

Harald zur Hausen (Nobel Laureate)

PL-42

Preventive Vaccination Against Cancers Caused by Infections

10:30

11:15

a.m.

Location: Auditorium

Muhammad Iqbal Choudhary

PL-43

Cost Effective Lead Discovery and Development – A New Paradigm

COFFEE BREAK: 11:15 – 11:45 a.m.

Lecture Hall  1

(B-104)

Lecture Hall 2

(B-121)

Lecture Hall No. 3

(B-217)

Lecture Hall 4

(C-106)

Lecture Hall 5

(B-116)

Lecture Hall 6

(B-215)

Drug Metabolism

Hot Topics in HIV Research

Cardiovascular Drug Discovery & Therapy

Innovative Drug Discovery & Nanotechnology

Anti-Cancer Drug Discovery & Therapy

Enabling Future Pharma: Nonprofits Drive Bench to Bedside Innovation

Chairman: D.M. Stresser

Co-Chairman: M.W. Sinz

Chairman: H. Itoh

Co-Chairman: Y.  Suzuki

Chairman: T.K. Chakraborty

Co-Chairman: S. Chandrasekhar

Chairman: A.C. Tedesco

Co-Chairman: A.G.A. Coombes

Chairman: S. Ayrapetyan

Co-Chairman: A. Boumendjel

Chairman: W.R. Hume

Co-Chairman: J.M. Shaeffer

11:45

12:20

p.m.

Chandra Prakash

SIL-44

Mechanism of Drug Toxicity and Relevance to Pharmaceutical Development

11:45

12:15

p.m.

Atsushi Koito

IL-45

Intrinsic Restriction Activity by APOBEC Enzymes Against HIV and Retroelement

11:45

12:15

 p.m.

Dipak P. Ramji

IL-46

Cytokines, Macrophages and Atherosclerosis

11:45

12:15

 p.m.

Martin J. Korbling

IL-47

Potential Removal of Circulating Tumor Cells by Photothermoablation Using Gold-Nanoparticle Constructs

11:45

12:15

p.m.

William B. Weglicki

IL-48

Neurogenic Inflammation and Cardiac Dysfunction due to Hypomagnesemia during EGFR-Tyrosine Kinase Inhibition

11:45

12:15

p.m.

Bernard Munos

IL-49

How much does it Really Cost to Develop a Drug for Rare and Neglected Diseases?

12:20

12:50

p.m.

Suresh Balani

IL-50

Anticipated Key Changes in the FDA’s Draft DDI Guidance, and Emerging Differences

12:15

12:45

p.m.

Hiroshi Ohrui

IL-51

Development of Modified Nucleosides that have Extremely High Anti-HIV Activity and Low Toxicity and Prevent the Emergence of Resistant HIV Mutants, and a Proposed Structure of Modified Nucleoside Expected to have High Antiviral Activity and Low Toxicity

12:15

12:45

p.m.

Tamer Elbayoumi

IL-52

Mitochondria-specific Nano-emulsified Therapy for Cardiovascular Protection Against Doxorubicin-induced Oxidative and Non-oxidative Toxicities

12:15

12:45

p.m.

Louis X. Tiefenauer

IL-53

Membrane Proteins in Stable Lipid Bilayers for Functional Studies and Applications

12:15

12:45

p.m.

Theresia Thalhammer

IL-54

Expression of Transport Proteins from the OATP Family in Solid Tumors: Potential Targets for Tumor Therapy

12:15

12:45

 p.m.

John A. Hardin

IL-55

The Role of Patient Advocacy Organizations in Drug Discovery and Development in the New Environment of Health Care

12:50

1:20

p.m.

Mehran Moghaddam

IL-56

Discovery of CC-930, an Orally Active Anti-fibrotic JNK Inhibitor

12:45

1:15

p.m.

Chatchai Tayapiwatana

IL-57

Zinc Finger Protein Designed to Target 2-LTR-circle Junctions Interferes with HIV Integration

12:45

1:15

p.m.

William B. Weglicki

IL-58

Iron-overload Cardiomyopathy: Lysosomotropic Mechanisms of Protection by Beta Blockers

12:45

1:15

p.m.

Roland H. Stauber

IL-59

Proteomic Profiling of the Dynamic Nanoparticle-serum Protein Corona – Implications for Biomedical Applications

12:45

1:15

p.m.

Caroline van Haaften

IL-60

A New Anti-cancer Drug Against Ovarian Cancer

12:45

1:20

p.m.

Rathnam Chaguturu

SIL-61

Enabling New Pharma: Drug Repurposing Efforts Go Mainstream

LUNCH BREAK: 01:20 – 02:45 p.m.

Lecture Hall 1

(B-104)

Lecture Hall 2

(B-121)

Lecture Hall 3

(B-217)

Lecture Hall 4

(C-106)

Lecture Hall 5

(B-116) 

Lecture Hall 6

(B-215)

Drug Metabolism

CNS Drug Discovery & Therapy

Cardiovascular Drug Discovery & Therapy

Drug Discovery in Preclinical Research / Hot Topics in Drug Targets

Anti-Cancer Drug Discovery & Therapy

Enabling Future Pharma: Nonprofits Drive Bench to Bedside Innovation

Chairman:  C. Prakash

Co-Chairman: S. Balani

Chairman: D.K. Lahiri

Co-Chairman: Z. Helyes

Chairman: C. A.-Blais

Co-Chairman: D.P. Ramji

Chairman: R. Stocklin 

Co-Chairman: N.I. Syed

Chairman: M.I. Choudhary

Co-Chairman: M. Wang

Chairman: B. Munos

Co-Chairman: J. Hardin

2:45

3:15

p.m.

Juan Ausio

IL-62

Molecular Determinants of the Interaction of Anthracyclines with Chromatin

2:45

3:15

p.m.

Taleb H. Al-Tel

IL-63

An Appraisal for the Development of Therapeutics for Alzheimer’s Disease: Design, Synthesis and Qualitative Structure Activity Evaluations of Novel β-Secretase Inhibitors

2:45

3:15

p.m.

Claudia Gragnoli

IL-64

Proteasome Modulator 9 and Depression

2:45

3:15

p.m.

Michael Hust

IL-65

Phage Display for the Selection of Immunogenic Proteins for Diagnostics and Vaccine Development

2:45

3:05

p.m.

Riyaz Basha

SL-66

Towards Improving Therapeutic Response in Pancreatic Cancer

2:45

3:15

p.m.

Rainer Henning

IL-67

ApoScience AG: Creating an Innovative Regenerative Medicine Company through a Public-private Partnership.  An Austrian Experience

3:15

3:45

p.m.

David M. Stresser

IL-68

Efficient Testing for Metabolism-based DDIs in Drug Discovery and the Implications for Concordance with Mandated Assay Methodologies Used in Drug Development

3:15

3:35

p.m.

Youssef Sari

SL-69

Glutamate Transporter 1: Potential Target for the Treatment of Drug Abuse and Neurodegenerative Diseases

3:15

3:45

p.m.

Shazia Anjum

IL-70

New NO – Releasing Anti Ischemic Agents: Using Pyridoxine as a Template

3:15

3:35

p.m.

Predrag Novak

SL-71

How do Macrolide Antibiotics Interact with Bacterial Ribosomes?

3:05

3:25

p.m.

Sadanori Takeo

SL-72

Feasibility Study for Biweekly Administration of Cisplatin Plus Vinorelbine as Adjuvant-chemotherapy for Completely Resected Non-small Cell Lung Cancer Patients in a Japanese Population

3:15

3:45

p.m.

Deborah Szafir

IL-73

Discover Eu2P: The First European Programme in Pharma-covigilance and Pharma-coepidemiology

3:45 4:15

p.m.

Michael W. Sinz

IL-74

An IGF-IR Inhibitor Induces CYP3A4 Expression through a PXR-independent, Non-canonical CAR-related Mechanism

3:35

3:55

p.m.

Vesna Radojevic

SL-75

Somatostatin in Mammalian Cochlea: It is a Potential Therapeutic with Protective Effect on Cochlea

3:45

4:05

p.m.

Zhangyin Ming

SL-76

Effects of Neferine on Platelet Aggregation and Disaggregation

3:35

3:55

p.m.

A. Manaf Ali

SL-77

In-vivo Antileukemic Activity of Goniothalamin

3:25

3:45

p.m.

Fehmida Fasim

SL-78

Sequence-dependent Synergism from Combinations of Cisplatin and Designed Transplatinums in Human Ovarian Tumour Models

3:45

4:15

p.m.

Wyatt R. Hume

IL-79

Using Public Investments in Research Optimally in Support of Industry

4:15

4:45

p.m.

Amin Kamel

IL-80

Deuterated Drug Approach to Mitigate Formation of Reactive Metabolites During Drug Discovery

3:55

4:15

p.m.

Razia Khanam

SL-81

Evaluation of Antidepressant Effects of Celecoxib (COX 2 Inhibitor) and its Combination with Duloxetin (SNRI) in Stressed Mice

4:05

4:25

p.m.

Mikhail Rudenko

SL-82

New Method for Monitoring the Effectiveness of Drugs Impact on Cardiovascular System

3:55

4:15

p.m.

Amina El-Gezeery

SL-83

On the Protective Effect of Omega-3 Against Propionic Acid-induced Neurotoxicity in Rat Pups

3:45

4:05

p.m.

Amr Amin

SL-84

Saffron: A Potential Target for a Novel Anti-cancer Drug Against Hepatocellular Carcinoma

4:15

4:45

p.m.

James M. Shaeffer

IL-85

Staying Competitive: Creating and Fostering Innovation in the Work Place

4:45

5:15

p.m.

Shawn Harriman

IL-86

Using PK/PD to Define Target Profile Earlier During Drug Discovery

4:15

4:45

p.m.

Antonio Y. Hardan

IL-87

A Randomized Controlled Trial of Oral N-Acetylcysteine in Children with Autism

4:25

4:45

p.m.

Moses Kayode Omole

SL-88

Knowledge of Disease and Adherence to Drug Therapy in Persons with Type 2 Diabetes and Hypertension

4:15

4:35

p.m.

Faten Khorshid

SL-89

Tumor Lung Cancer Model for Assessing Anti-neoplastic Effect of PMF in Rodents: Histopathological Study

4:05

4:25

p.m.

Shirley Knauer

SL-90

Induction of Tumor Cell Death by Survivin Nuclear Export Inhibitors

4:45

5:15

p.m.

Ulf Nehrbass

IL-91

Translational Research Based on Imaging Based Drug Discovery

4:45

5:05

p.m.

Sandeep Kumar Shukla

SL-92

The Targeted Delivery of CNS Drug Across the Blood Brain Barrier; Chemical Modification of Drug or Drug Nanopartical

4:45

5:05

p.m.

Ashour S. Eljamil

SL-93

Significant Differences Between LDL-cholesterol Level Obtained by Friedewald Formula and A Direct Method

4:35

4:55

p.m.

Hussin A. Rothan

SL-94

The N-terminal Residues of NS2B Cofactor Represent the Core Interaction Region with NS3 that are Critical for Entire Activity of Dengue Virus NS3 Serine Protease

4:25

4:55

p.m.

Bernd Kaina

IL-95

The 06-Alkylguanine Response: Mechanisms and Implications for Cancer Therapy

5:15

5:45

p.m.

Assem S. el Baghdady

IL-96

Something Old, Something New – Something Borrowed and Something Blue!?  Innovative / Recycled – Model forDrug Development Partnership

SOCIAL MIXER & POSTER PRESENTATION: 5:00 – 6:15 p.m.

The buses will leave for hotels at 6:15 p.m.

DAY 3: Tuesday, February 14, 2012

JOINT PLENARY SESSION

Time

Chairman: R. Zimmerman

Co-Chairman: C. Prakash

Speaker

Title

9:00

9:45

a.m.

Location: Auditorium

Ferid Murad (Nobel Laureate)

PL-97

Discovery of Nitric Oxide and Cyclic GMP Cell Signaling and their Role in Drug Development

9:45

10:30

a.m.

Location: Auditorium

Jean-Marie Lehn (Nobel Laureate)

PL-98

From Supramolecular Chemistry towards Adaptive Chemistry: Bioorganic and Drug Discovery Aspects

INAUGURAL CEREMONY OF CURRENT BIOTECHNOLOGY JOURNAL

PUBLISHED BY BENTHAM SCIENCE PUBLISHERS

10:30 – 10:40 a.m.

COFFEE BREAK: 10:40 – 11:15 a.m.

Lecture Hall 1

(B-104)

Lecture Hall 2

(B-121)

Lecture Hall 3

(B-217)

Lecture Hall 4

(C-106)

Lecture Hall 5

(B-116)

Innovative Drug Discovery & Nanotechnology / Structural Biology

Translational Medicine / Drug Metabolism

Recent Advances in Patient Treatment & Care

Enabling Future Pharma: Nonprofits Drive Bench to Bedside Innovation / Drug Delivery & Targeting

Pulmonary Drug Discovery Therapy / Proteomics & Bioinformatics / In-Silico Drug Design and In-Silico Screening / Pharmacogenomics / Combinatorial Chemistry / Innovative Drug Discovery & Nanotechnology

Chairman: D.M. Stresser

Co-Chairman: A. El-Gezeery

Chairman: P. Novak

Co-Chairman: C. Gragnoli

Chairman: T. Elbayoumi

Co-Chairman: M.K. Omole

Chairman: J.A. Hardin

Co-Chairman: D. Panigrahy

Chairman: I. Silva

Co-Chairman: A.M. Ali

11:15

11:45

a.m.

Anneliese Schrott-Fischer

IL-99

Nanomedicine and Inner Ear

11:15

11:45

a.m.

Inhee Mook-Jung

IL-100

Human Serum Transthyretin Levels Correlate Inversely with Alzheimer Disease

11:15

11:45

a.m.

Christiane Auray-Blais

IL-101

Biomarker Discovery for Fabry Disease Using a Mass Spectrometry Approach

11:15

11:45

a.m.

Dipak P. Ramji

IL-102

Atherosclerosis: Molecular Mechanisms, Therapeutic Targets and Translational Challenges

11:15

11:35

a.m.

Y.S. Prakash

SL-103

Sex Steroids in Asthma

11:45

12:15

p.m.

Maxim Ryadnov

IL-104

Peptide Design and Self-assembly for Biomedical Applications

11:45

12:05

p.m.

Zsuzsanna Helyes

SL-105

Pituitary Adenylate Cyclase-activating Polypeptide Plays an Important Role in a Mouse Model of Trigeminovascular Activation

11:45

12:05

p.m.

Rolf-Peter Mueller

SL-106

Intensity of Combined Modality Chemotherapy and Pet-guided Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma

11:45

12:15

p.m.

Philip D. Cotter

IL-107

A New Paradigm for Personalized Medicine and Companion Diagnostics: The Contract Diagnostics Organization

11:35

11:55

a.m.

Janos Posfai

SL-108

Domain Fusions in Restriction-Modification System Enzymes and Genomic Contexts of Fusions

12:15

12:35

p.m.

Sergey Tarasov

SL-109

Advantages of Using Antibodies in Ultra Low Doses as a New Pharmacological Approach

12:05

12:25

p.m.

Shivendra V. Singh

SL-110

Prostate Cancer Prevention with Bioactive Food Components

12:05

12:25

p.m.

Alberto Priori

SL-111

Transcranial Direct Current Stimulation (tDCS) as Potential Therapeutic Tools for Neurological and Psychiatric Disorders

12:15

12:45

p.m.

Jay F. Dorsey

IL-112

Enhancing the Efficacy of Drug-loaded Nanocarrier (DLN) Against Brain Tumors by Targeted Radiation Therapy

11:55

12:15

p.m.

Mahmoud ElHefnawi

SL-113

A Novel in-silico Protocol for the Development and Evaluation of New HCV Polymerase Inhibitors

12:35

1:05

p.m.

Issac C. Sanchez

IL-114

Introducing Computational Structural Spectroscopy of Globular Proteins

12:25

12:45

p.m.

Rajesh Agarwal

SL-115

Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy

12:25

12:45

p.m.

Bassam Alfeeli

SL-116

Toward Handheld Diagnostics of Cancer Biomarkers in Breath: Microfabricated Gas Chromatography Systems

12:45

1:15

p.m.

Sergio Daniel Bergese

IL-117

The Efficacy of EXPAREL^TM, a Multivesicular Liposomal Extended Release Bupivacaine

12:15

12:35

p.m.

Maha M. Saber-Ayad

SL-118

Pharmaco-genomics and the Promise of Individualized Therapy

1:05

1:35

p.m.

Niels Volkmann

IL-119

Towards Understanding the Structural Basis of Arp2/3-mediated Actin-branch Formation

12:45

1:05

p.m.

Janos Posfai

SL-120

Developmental Self Organization and Autism – A Hypothesis

12:45

1:05

p.m.

Audrius Andrijauskas

SL-121

Goal Directed Fluid Therapy Revised: Indirect Monitoring of Interstitial Fluid Accumulation During Mini Fluid Challenges with Crystalloids

12:35

12:55

p.m.

Abdollah Javidan

SL-122

The Synthesis of Some Tricyclic Benzodiazepinones

1:05

1:35

p.m.

Subrahmanyam Vangala

IL-123

Translational Drug Discovery Research: Integration of Medicinal Chemistry, Computational Modeling, Pharmacology, ADME and Toxicology

1:05

1:25

p.m.

Mehmet Ozbilen

SL-124

Systematic Review and Meta-analysis of Anticholinergic Side Effects of Long-acting Antipsychotics

12:55

1:25

p.m.

Francisco Bulnes

IL-125

Combination of Quantum Factors in Integral Mono-Pharmacists and Their Actions in Cellular Regeneration and Total Cure

LUNCH BREAK: 01:25 – 2:30 p.m.

Lecture Hall 1

(B-104)

Lecture Hall 2

(B-121)

Lecture Hall 3

(B-217)

Lecture Hall 4

(C-106)

Lecture Hall 5

(B-116)

Stereoselective Synthesis of Bioactive Compounds / Nutraceutical Drug Discovery & Therapy / Diabetes & Obesity Drug Discovery & Therapy

Inflammation and Immunology

Hot Topics in HIV Research / Hot Topics in Medicinal Chemistry / Pharmaceutical Research & Development

Women’s Health Drug Discovery & Therapy / Drug Discovery in Preclinical Research

CNS Drug Discovery & Therapy / Hot Topics in Natural Products

Chairman: J. Wu

Co-Chairman: A. Hamad

Chairman: S. Kubo

Co-Chairman: M. Hust

Chairman: S.J. Faulkner

Co-Chairman: T.-L. Li

Chairman: R.H. Stauber

Co-Chairman: M. Wiltgen

Chairman: M. Ashina

Co-Chairman: E. Thiel

2:30

3:00

p.m.

Rodney A. Fernandes

IL-126

Development of Dimeric Fischer Carbenes: A Bidirectional Dotz Benzannulation Approach to Dimeric Pyranonaphthoquinones

2:30

3:00

p.m.

D.D. Adams

IL-127

Prophylaxis of the Autoimmune Diseases

2:30

3:00

p.m.

Jamil S. Saad

IL-128

Structural Biology of HIV-host Interactions: Basis for Therapeutic Intervention

2:30

3:00

p.m.

Allan G.A. Coombes

IL-129

Controlled Microbicide Delivery Using Intra-vaginal Polymeric Matrices

2:30

3:00

p.m.

H.C. Pant

IL-130

TFP5: A Peptide Derived from the Cdk5 Regulator p35, Crosses Blood Brain Barrier and Resources Phenotypes of AD Model Mice

3:00

3:20

p.m.

Victor Borovkov

SL-131

Optically Active Compounds: Supramolecular Absolute Configuration Determination and Prospects in Stereoselective Catalysis

3:00

3:30

p.m.

Akinori Takaoka

IL-132

ZAPS as a Booster of Innate Immune Signaling for Antiviral Defense Against Influenza Virus Infection

3:00

3:20

 p.m.

Xiang-Qu Xie

SL-133

New Drug Target and Novel Chemical Agents for Multiple Myeloma Therapeutic Interventions

3:00

3:20

p.m.

George Falkay

SL-134

Increased Tocolytic Effect of Nifedipine by ABCG₂ Efflux Protein Inhibitor KO134 in Rat in-vivo

3:00

3:20

p.m.

Wei-Jane Chen

SL-135

Fast versus Slow Strategy of Switching Patients with Schizophrenia to Aripiprazole from Other Antipsychotics

3:20

3:40

p.m.

Abdollah Javidan

SL-136

Synthesis of Enantiomerically Pure Spirooxindoles Using a Three Component Reaction via 1:3 Dipolar Cycloaddition Reaction

3:30

4:00

p.m.

Kazuyuki Yoshizaki

IL-137

A Humanized Anti-IL-6 Receptor Antibody for the Treatment of Chronic Inflammatory Diseases

3:20

3:40

p.m.

Faten Khorshid

SL-138

An ointment contain 3% of PMF Components Showed Promising Results for Treatment of Psoriasis

3:20

3:40

p.m.

Shao-fen Zhang

SL-139

Clinical Research on Gonadotropin Releasing Hormone Analogue and Estrogen-progestogen Add-back Therapy in the Treatment of Endometriosis

3:20

3:40

p.m.

Moses Kayode Omole

SL-140

A Survey of Rational Prescriptions of Penicillin and Cephalosporin Antibiotics in Sacred Heart Hospital Lantoro Abeokuta in South West Nigeria

3:40

4:10

p.m.

Debomoy K. Lahiri

IL-141

Neuroprotective and Neuropreservative Effects of Nutraceuticals in Neuronal Culture Systems: Potential Preventive/Therapeutic Strategies in Alzheimer’s Disease (AD)

4:00

4:20

p.m.

Erika Pinter

SL-142

SST4 Somatostatin Receptor as a Promising Drug Target

3:40

4:00

p.m.

Ayman Allahham

SL-143

Incorporation of Micronised Poorly Water-soluble Additive into Indomethacin Formulated Tablets.  Effect of Carrier Type, Additive and Drug Concentration on Dissolution: Is it Due to Micronisation?

3:40

4:00

p.m.

Sadia Sarwar Dogar

SL-144

Possible Anti-uterus Cancer Potential of Potent Herb Eclipta alba as Exhibited Through Anti-estrogenic Activity

3:40

4:00

p.m.

Vicente G. Villarrubia

SL-145

A Standardized Formulation of Organic Extra Virgin Olive Oils (oHo^®TM) Decreases lipid Cardiovascular Risk Factors in Renal and Psoriasis Patients.  oHo Intake, Along with the Topic Application of oHo-based Dermal Products (oHo-DP), Ameliorates Notably the Clinical Evolution of Psoriasis, Atopic Dermatitis and Graft vs Host Skin Disease (GvHSD)

4:10

4:30

p.m.

Abdullah bin Habeeballah bin Abdullah Juma

SL-146

The Discovery of the Efficacy of Lepidium sativum Seeds on Fracture Healings

4:20

4:40

p.m.

Manal Abdel-Salam Abdel-Hafez

SL-147

Gene Polymorphisms of TNF-a and IL-10 Related to Rheumatic Heart Disease

4:00

4:20

p.m.

Yi Jiang

SL-148

Animal Fecal Actinomycetes, A New Source of Drug Discovery

4:00

4:30

p.m.

Naweed I. Syed

IL-149

Novel Brain-chip Technology provides Breakthrough for High to Mid-throughput Drug Screening of Neuronal and Cardiac Cells

4:00

4:20

p.m.

Nooshin Bagherani

SL-150

Comparison of Therapeutic Efficacy of Topical Corticosteroid and Oral Zinc Sulfate-topical Corticosteroid Combination in the Treatment of Vitiligo Patients: A Clinical Trials

4:30

4:50

p.m.

Vikram Gota

SL-151

A Phase I Safety and Pharmacokinetics Study of Withaferin-A in Patients with Advanced Stage High Grade Osteosarcoma

4:40

5:00

p.m.

Mohamed Nabih Abdel Rahman

SL-152

Study of Atorvastatin in Experimental Allergic Airway Inflammation in Mice

4:20

4:40

p.m.

Arman Zargaran

SL-153

Pharmaceutical Evaluation of a Traditional Formulation: Ergh-al-Nessa Pill (Hab)

4:30

5:00

p.m.

Reto Stocklin

IL-154

NextGen Venomics for Peptide Drug Discovery and Lead Optimisation Using Melusing^®: Natural Synthetic and Virtual Venom Libraries

4:20

4:40

p.m.

Zafar Iqbal

SL-155

In vitro Anthelmintic  Activity of Different Fractions of Azadirachtaindica A. Juss Seeds

4:50

5:10

p.m.

Majeed H. Majeed Al-Sarry

SL-156

Role of Grape Seed Extract as Popular Medication in Diabetes Mellitus

4:40

5:00

p.m.

Ayda Hosseinkhani

SL-157

Abkama a Traditional Dosage Form as a Source for Novel Drug Discovery

5:00

5:20

p.m.

Martin Trapecar

SL-158

Untransformed Functional 3D Cell Models of the Gut: The New Frontier for Discovery and Evaluation of Oral Medication and nutraceuticals

4:40

5:00

p.m.

Zia-ud-Din Sindhu

SL-159

Discovery of New Ixodicides: From Documentation of Ethno-veterinary Practices to Scientific Validation in Laboratory

POSTER PRESENTATION: 5:00 – 6:00 p.m.

Posters Session: 5:00 – 6:00 p.m.

Departure for Gala Dinner: Departure at 6:00 p.m.

The buses will leave for hotels at 8:30 p.m.

DAY 4: Wednesday, February 15, 2012

JOINT PLENARY SESSION

Time

Chairman: D.K. Lahiri

Co-Chairman: M. I. Choudhary

Speaker

Title

8:45  9:30

a.m.

Location: Auditorium

Ron Zimmerman

PL-160

Plx Pharma – Developing A GI Safer Aspirin

9:30

10:15

a.m.

Location: Auditorium

John W. Hadden II

PL-161

IRX-2 A Novel Immunomodulator for Cancer

Lecture Hall 1

(B-104)

Lecture Hall 2

(B-121)

Lecture Hall 3

(B-217)

Lecture Hall 4

(C-106)

Lecture Hall 5

(B-116)

Enabling Technologies / Diabetes & Obesity Drug Discovery & Therapy

 Inflammation and Immunology

Regenerative Medicine

Pharmaceutical Research & Development

Recent Advances in Patient Treatment & Care / Anti-Cancer Drug Discovery & Therapy

Chairman: S. Sultana

Co-Chairman: A. Hamad

Chairman: M.  Ozbilen

Co-Chairman: A. Koito

Chairman: M.E. Lamas

Co-Chairman: A.C. Tedesco

Chairman: A. Zargaran

Co-Chairman: Y. Jiang

Chairman: R. Kumar

Co-Chairman: X.Q. Xie

10:15

10:35

a.m.

Alexey Kopylov

SL-162

Modular Construction of Aptameric Nanostructures: Anti-thrombin Aptamers

10:15

10:45

a.m.

Seita Kubo

IL-163

CpG-ODN Induces CD274 Expression on Human B Cells and CpG ODN-treated B Cells Decreased IL-5 Production from Antigen-stimulated Human CD4+ Cells

10:15

10:45

a.m.

Stephen J. Faulkner

IL-164

Safety and Complications Reporting Update on the Re-implantation of Culture-Expanded Mesenchymal Stem Cells Using Autologous Platelet Lysate Technique

10:15

10:35

a.m.

Mehdi Sakha

SL-165

Treatment of Highly Fatal Oleander Poisoning in Man and Animals in Iran, an Overview

10:15

10:45

a.m.

Pedro Oliveira

IL-166

Users as Developers and Entrepreneurs of Medical Treatments/Devices: The Case of Patients and Their Families and Friends

10:35

10:55

a.m.

 Kam Y.J. Zhang

SL-167

Scaffold-based Drug Design: An Efficient Tool for the Discovery of New Molecular Entities

10:45

11:15

a.m.

D.D. Adams

IL-168

The Essential Role of the Histocompatibility System for Virus Defence and how Transplant Surgeons can Xenograft without Rejection

10:45

11:15

a.m.

Aris Lacis

IL-169

Method of Choice for Stem Cell Intramyocardial Implantation in Children

10:35

10:55

a.m.

Mohammad A. Al-Sayah

SL-170

The Use of Analytical Chemistry Technologies During the Synthesis of Active Pharmaceutical Ingredients

10:45

11:15

a.m.

Dong-Lu Shi

IL-171

Self-sacrificed PEG-sheddable Micelles Based on Disulfide Bond Conjugation for Glutathione-mediated Intracellular Drug Delivery

10:55

11:25

a.m.

Jerry Jiayu Liao

IL-172

Small Molecular Modulators for GLP1 Receptor

11:15

11:45

a.m.

Faikah Gueler

IL-173

Treatment with a PKC Alpha/Beta Inhibitor Attenuates Hypoxia Induced Interstitial Renal Fibrosis and Inflammation via Reduced Activation of TGF-beta Signaling

11:15

11:35

a.m.

Abdullah bin Habeeballah bin Abdullah Juma

SL-174

A Very Rare Combination of Nail – Patella Syndrome (NPS) and Down’s Syndrome (DS): The First Described Study

10:55

11:15

a.m.

Elena Boldyreva

SL-175

Solid-state Chemistry and New Drug Forms

11:15

11:35

a.m.

V. Gardsvoll

SL-176

TITLE AWAITED

COFFEE BREAK: 11:35 – 12:00 p.m.

Lecture Hall 1

(B-104)

Lecture Hall 2

(B-121)

Lecture Hall 3

(B-217)

Lecture Hall 4

(C-106)

Lecture Hall 5

(B-116)

Diabetes & Obesity Drug Discovery & Therapy/ Drug Discovery in Preclinical Research / Cardiovascular Drug Discovery & Therapy

Pharmaceutical Biotechnology / Drug Delivery & Targeting

Anti-Cancer Drug Discovery & Therapy

Anti-Infectives / Protein & Peptide Sciences

 Regenerative Medicine / Inflammation and Immunology / Enabling Technologies / Biologics

Chairman: M. Saber

Co-Chairman: J.J. Liao

Chairman: M.I. Choudhary

Co-Chairman: J.S. Saad

Chairman: O. Larsson

Co-Chairman: P. Cotter

Chairman: D.P. Ramji

Co-Chairman: N. Volkmann

Chairman:  S.J. Faulkner

Co-Chairman: A. Lacis

12:00

12:30

p.m.

Abdel Hamad

IL-177

Immunotherapy for Type 1 Diabetes: Necessity, Challenges and Unconventional Opportunities

12:00

12:30

p.m.

Michael Hust

IL-178

Antibody Phage Display for Diagnostics and Therapy

12:00

12:30

p.m.

Sinerik Ayrapetyan

IL-179

The High Affinity Ouabain Receptors’ Dysfunction as a Primary Mechanism for Cancerogenesis

12:00

12:30

p.m.

Youssef L. Bennani

IL-180

Discovery and Development of the HCV-protease Inhibitor: Incivek

12:00

12:20

p.m.

Kamal Ameis

SL-181

Degeneration / Regeneration as a Mechanism Contributing to the Effect of Manual Acupuncture-Induced Injury on Rat Skeletal Muscle

12:30

1:00

p.m.

Marco Wiltgen

IL-182

Measurement of the Diabetes Associated Antigen GAD 65 in Human Sera

12:30

1:00

p.m.

Chil-Yong Kang

IL-183

Creation of Universal Vectors for Prophylactic and/or Therapeutic Recombinant Virus Vaccines

12:30

1:00

p.m.

Tamer Elbayoumi

IL-184

Novel Genistein-loaded Lipidic Nanocarrier Adjuvants Enhance Anticancer Efficacy and Overcome Cancer Resistance to Chemotherapy

12:30

1:00

p.m.

Avrelija Cencic

IL-185

The Frontiers in Antiviral Therapies: From Back to Nature to High Biotech Approach

12:20

12:50

p.m.

Ram Devireddy

IL-186

Rational Design of Poly (L-lactic acid) Staffolds

1:00

1:20

p.m.

Basiouny El-Gamal

SL-187

L-arginine Ameliorates Intralipid-induced Dyslipidemia and Hyperglycemia in Experimental Animals

1:00

1:30

p.m.

Icy D’Silva

IL-188

Recombinant Technology in Drug Discovery and Therapy

1:00

1:30

p.m.

Wael M. ElShamy

IL-189

Geminin Overexpression Induces Imatinib Sensitive Mammary Tumors via Nuclear C-Abl

1:00

1:20

p.m.

Alexey Kopylov

SL-190

Interface Inhibitors of Macromolecular Interactions – Ribosomal Paradigm for Creation of Novel Antibiotics

12:50

1:10

p.m.

Dipak Panigrahy

SL-191

Expoxy-eicosanoids Promote Tissue and Organ Regeneration

1:20

1:40

p.m.

A. Manaf Ali

SL-192

 In-vitro and in-vivo Antileukemic Activities of New Castle Disease Virus Strains Af2240 and V4-Upm

1:30

1:50

p.m.

Chung-Hsuan (Winston) Chen

SL-193

Novel Mass Spectrometry Technology Development for Bioparticle Measurement and Proteomics Applications

1:30

2:00

p.m.